Posted by Michael Wonder on 13 Oct 2017
Decision to fund dexamethasone implants (Ozurdex)
13 October 2016 - PHARMAC is pleased to announce the approval of an agreement with Allergan for the listing of dexamethasone ocular implants in Section B (Community) and in Part II of Section H (Hospital) of the Pharmaceutical Schedule.
This was the subject of a consultation letter dated 15 September 2017.
The funding of dexamethasone ocular implants means that from 1 November 2017, a new long-acting pharmaceutical, with a different mechanism of action to currently-available treatments, will be available and funded for eligible people with diabetic macular oedema.
